Zacks: Brokerages Expect Intellia Therapeutics Inc (NTLA) to Announce -$0.57 EPS

Brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to announce ($0.57) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.50). Intellia Therapeutics reported earnings of ($0.45) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 26.7%. The business is expected to issue its next earnings results on Tuesday, August 7th.

On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.33) to ($1.65). For the next year, analysts anticipate that the firm will post earnings of ($2.71) per share, with EPS estimates ranging from ($3.09) to ($2.11). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, May 1st. The company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.07. The business had revenue of $7.47 million during the quarter, compared to analyst estimates of $6.14 million. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%.

Several analysts have recently weighed in on the company. BidaskClub upgraded Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 13th. JMP Securities initiated coverage on Intellia Therapeutics in a report on Thursday, March 8th. They set an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a report on Thursday, March 15th. Leerink Swann reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Finally, ValuEngine raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $34.83.

Shares of Intellia Therapeutics traded up $1.78, hitting $31.44, during trading on Friday, MarketBeat reports. The stock had a trading volume of 854,214 shares, compared to its average volume of 1,064,537. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -16.60 and a beta of 3.20. Intellia Therapeutics has a fifty-two week low of $14.45 and a fifty-two week high of $35.99.

In related news, insider John M. Leonard sold 8,400 shares of the company’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jean Francois Formela sold 6,686 shares of the company’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,772 shares of company stock valued at $555,958. 12.80% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in Intellia Therapeutics by 521.7% during the first quarter. Royal Bank of Canada now owns 30,320 shares of the company’s stock valued at $640,000 after buying an additional 25,443 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Intellia Therapeutics during the first quarter valued at $252,000. Barclays PLC raised its position in Intellia Therapeutics by 112.8% during the first quarter. Barclays PLC now owns 19,778 shares of the company’s stock valued at $416,000 after buying an additional 10,483 shares during the period. UBS Group AG raised its position in Intellia Therapeutics by 131.6% during the first quarter. UBS Group AG now owns 191,616 shares of the company’s stock valued at $4,041,000 after buying an additional 108,878 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in Intellia Therapeutics during the first quarter valued at $1,159,000. 60.74% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply